5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 2, 2004, Pages 825-832

  Bhattacharya, Anindya ^a,b   Schenck, Kathryn W ^a   Xu, Yao Chang ^a   Nisenbaum, Laura ^a   Galbreath, Elizabeth ^a   Cohen, Marlene L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 2 METHOXYPHENYLPIPERAZIDE DERIVATIVE; ANTIBODY; CD31 ANTIBODY; CD31 ANTIGEN; N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; POTASSIUM CHLORIDE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; BENZOPYRAN DERIVATIVE; CD34 ANTIGEN; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; VASOCONSTRICTOR AGENT;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BASILAR ARTERY; BINDING AFFINITY; CONTROLLED STUDY; ENDOTHELIUM CELL; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SAPHENOUS VEIN; SEROTONINERGIC SYSTEM; SMOOTH MUSCLE CONTRACTILITY; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASOCONSTRICTION; ANIMAL; BINDING SITE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD34; BASILAR ARTERY; BENZOPYRANS; BINDING SITES; ENDOTHELIUM, VASCULAR; NG-NITROARGININE METHYL ESTER; PIPERAZINES; RABBITS; RECEPTOR, SEROTONIN, 5-HT1B; SAPHENOUS VEIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SUMATRIPTAN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 2142805873     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.062653     Document Type: Article

References (29)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. 1D subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 354:237-244.
3. Bhattacharya A, Schenck KW, and Cohen ML (2003) Amplification of sumatriptan-induced contraction in rabbit saphenous vein but not in basilar artery. Am J Physiol 284:H719-H726.
4. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129:501-508.
5. Bouchelet I, Cohen Z, Casae B, Seguela P, and Hamel E (1996) Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. J Pharmacol Exp Ther 50:219-223.
6. Boulanger CM, Heymes C, Benessiano J, Geske RS, Levy BI, and Vanhoutte PM (1998) Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells. Circ Res 83:1271-1278.
7. Carel I, Ghaleh B, Edouard A, Dubois-Rande JL, Parsons AA, Giudicelli JF, and Berdeaux A (2001) Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br J Pharmacol 132:1071-1083.
8. Cohen ML, Johnson KW, Schenck KW, and Phebus LA (1997) Migraine therapy: relationship between serotoninergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalagia 17:631-638.
9. Cohen ML and Schenck KW (1999) 5-HydroxytryptaminelF receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin1F receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 290:935-939.
10. 2α. Br J Pharmacol 131:562-568.
11. 1D agonists: potential new treatment for migraine without cardiovascular side-effects. J Med Chem 41:2180-2183.
12. Furchgott RF and Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond) 288:373-376.
13. Gaddum JH (1957) Theories of drug antagonism. Pharmacol Rev 9:211-218.
14. 1B receptor. Eur J Pharmacol 367:283-290.
15. Hamel E (1999) The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurol Sci 26:S2-S6.
16. Hecker M, Cattaruzza M, and Wagner AH (1999) Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol 32:9-16.
17. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94:1123-1132.
18. Ishida T, Kawashima S, Hirata KI, Sakoda T, Shimokawa Y, Miwa Y, Inoue N, Ueyama T, Shiomi M, Akita H, et al. (2001) Serotonin-induced hypercontraction through 5-hydroytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 103:1289-1295.
19. 1B receptor antagonists. Bioorg Med Chem Lett 24:3183-3188.
20. MaassenVanDenbrink A, Reekers M, Bas WA, Ferrari MD, and Saxena PR (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25-30.
21. 1 receptor mediated-vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone. Pulm Pharmacol 7:65-72.
22. McGuire JJ, Ding H, and Triggle CR (2001) Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolarizing factor(s). Can J Physiol Pharmacol 79:443-470.
23. 1B/1D-receptor ligand flovatriptan in human isolated basilar and coronary arteries. J Cardiovsac Pharmacol 32:220-224.
24. 1D binding sites. Eur J Pharmacol 163:133-136.
25. Rasmussen K, Calligaro DO, Czachura JF, Dreshfield-Ahmad LJ, Evans DC, Hemrick-Luecke SK, Kallman M, Kendrick WT, Leander JD, Nelson DL, et al. (2000) The novel 5-hydroxytryptaminelA antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. J Pharmacol Exp Ther 294:688-700.
26. 1D receptor antagonist. Behav Brain Res 73:157-161.
27. 1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 119:35-42.
28. 1B receptors. Br J Pharmacol 120:153-159.
29. Zgombick JM, Weinshank RL, Macchi M, Schechter LE, Branchek TA, and Hartig PR (1991) Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype. Mol Pharmacol 40:1036-1042.